Longeveron to Present at the Planet MicroCap Showcase
25 avr. 2024 16h05 HE
|
Longeveron
Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
18 avr. 2024 16h05 HE
|
Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
17 avr. 2024 08h00 HE
|
Longeveron
Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15 avr. 2024 08h30 HE
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Announces Closing of $5.2 Million Public Offering
11 avr. 2024 17h17 HE
|
Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
Longeveron Announces Pricing of $5.25 Million Public Offering
08 avr. 2024 14h15 HE
|
Longeveron
Longeveron prices $5.15 million public offering with certain board member and insider participation.
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
08 avr. 2024 08h30 HE
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Longeveron Announces 1-for-10 Reverse Stock Split
19 mars 2024 16h01 HE
|
Longeveron
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical...
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
27 févr. 2024 16h05 HE
|
Longeveron
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of...
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
21 févr. 2024 16h05 HE
|
Longeveron
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...